VEGF-inhibitor group (n = 134) | EGFR-inhibitor group (n = 45) | P-value | |
---|---|---|---|
Sex (female) | 58 (43.3%) | 18 (40.0%) | 0.731a) |
Age (year) | 69 (33–85) | 66 (32–82) | 0.345b) |
Body surface area (m2) | 1.570 (1.192–2.010) | 1.583 (1.223–1.941) | 0.717b) |
BMI (kg/m2) | 21.9 (15.0–36.5) | 21.6 (15.9–33.8) | 0.958b) |
Primary rectal tumor | 44 (32.8%) | 17 (31.1%) | 0.588 |
Number of metastases (n) | 1 (1–5) | 1 (1–3) | 0.589b) |
Types of molecular-targeted drugs | Bevacizumab: 134 (100%) | Panitumumab: 40 (88.9%) | - |
Cetuximab: 5 (11.1%) | |||
Number of cytotoxic anticancer drugs used in combination (3/2/1) | 5/120/9 | 0/45/0 | 0.075a) |
Number of first-line treatments (n) | 10.5 (1–62) | 9 (1–40) | 0.454b) |
CV port construction, yes (n) | 110 (82.1%) | 45 (100%) | < 0.001a) |
Comorbid cardiac disease (n) | 2 (1.5%) | 3 (6.7%) | 0.601a) |
Comorbid hypertension (n) | 35 (26.1%) | 16 (35.6%) | 0.254a) |
Comorbid diabetes mellitus (n) | 17 (12.7%) | 5 (11.1%) | 1.000a) |
Concomitant use of hormonal agents (n) | 0 (0.0%) | 0 (0.0%) | - |
Concomitant use of hematopoietic agents (n) | 0 (0.0%) | 0 (0.0%) | - |
WBC count before starting treatment (× 103/μL) | 5.55 (2.3–14.4) | 5.90 (3.0–11.6) | 0.164b) |
Platelet count before starting treatment (× 103/μL) | 230.5 (79–693) | 246 (114–454) | 0.423b) |
Hemoglobin level before starting treatment (g/dL) | 11.6 (7.9–15.7) | 11.6 (6.5–16.4) | 0.552b) |
Number of risk factors (0/1/2/3) | 84/41/7/2 | 25/15/5/0 | 0.438a) |
Median number of days from treatment start date to thromboembolism onset date | 84.5 (18–200) | 101 (7–707) | 0.678b) |